Does mRNA SARS-CoV-2 vaccine influence patients' performance during IVF-ET cycle?

Citations of this article
Mendeley users who have this article in their library.

This article is free to access.


Objective: No information exists in the literature regarding the effect of mRNA SARS-CoV-2 vaccine on subsequent IVF cycle attempt. We therefore aim to assess the influence of mRNA SARS-CoV-2 vaccine on IVF treatments. Design: An observational study. Setting: A tertiary, university-affiliated medical center. Patients and Methods: All couples undergoing consecutive ovarian stimulation cycles for IVF before and after receiving mRNA SARS-CoV-2 vaccine, and reached the ovum pick-up (OPU) stage. The stimulation characteristics and embryological variables of couples undergoing IVF treatments after receiving mRNA SARS-CoV-2 vaccine were assessed and compared to their IVF cycles prior to vaccination. Main outcome measures: Stimulation characteristics and embryological variables. Results: Thirty-six couples resumed IVF treatment 7–85 days after receiving mRNA SARS-CoV-2 vaccine. No in-between cycles differences were observed in ovarian stimulation and embryological variables before and after receiving mRNA SARS-CoV-2 vaccination. Conclusions: mRNA SARS-CoV-2 vaccine did not affect patients’ performance or ovarian reserve in their immediate subsequent IVF cycle. Future larger studies with longer follow-up will be needed to validate our observations.




Orvieto, R., Noach-Hirsh, M., Segev-Zahav, A., Haas, J., Nahum, R., & Aizer, A. (2021). Does mRNA SARS-CoV-2 vaccine influence patients’ performance during IVF-ET cycle? Reproductive Biology and Endocrinology, 19(1).

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free